Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims: To evaluate the long‐term durability of the efficacy of alogliptin compared with glipizide in combination with metformin in people with type 2 diabetes inadequately controlled on stable‐dose metformin. Methods: This multicentre, double‐blind, active‐controlled study randomized 2639 patients aged 18–80 years to 104 weeks of treatment with metformin in addition to alogliptin 12.5 mg once daily (n = 880), alogliptin 25 mg once daily (n = 885) or glipizide 5 mg once daily, titrated to a maximum of 20 mg (n = 874). The primary endpoint was least square mean change from baseline in HbA1c level at 104 weeks. Results: The mean patient age was 55.4 years, the mean diabetes duration was 5.5 years and the mean baseline HbA1c was 7.6%. HbA1c reductions at week 104 were −0.68%, −0.72% and −0.59% for alogliptin 12.5 and 25 mg and glipizide, respectively [both doses met the criteria for non‐inferiority to glipizide (p<0.001); alogliptin 25 mg met superiority criteria (p=0.010)]. Fasting plasma glucose concentration decreased by 0.05 and 0.18 mmol/l for alogliptin 12.5 and 25 mg, respectively, and increased by 0.30 mmol/l for glipizide (p < 0.001 for both comparisons with glipizide). Mean weight changes were −0.68, −0.89 and 0.95 kg for alogliptin 12.5 and 25 mg and glipizide, respectively (p < 0.001 for both comparisons with glipizide). Hypoglycaemia occurred in 23.2% of patients in the glipizide group vs. 2.5 and 1.4% of patients in the alogliptin 12.5 and 25 mg groups, respectively. Pancreatitis occurred in one patient in the alogliptin 25 mg group and three in the glipizide group. Conclusions: Alogliptin efficacy was sustained over 2 years in patients with inadequate glycaemic control on metformin alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · cited 1×
“When first-line treatment with metformin proves ineffective or is not well tolerated, sulfonylureas represent the most common second-line treatment [2]; however, sulfonylurea therapy is associated with weight gain and a substantial risk of hypoglycaemia.”
BackgroundGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 2×
“Definitive findings on risk of MACE with alogliptin, however, are shown in the recent publication of the results of the EXAMINE trial [8].”
BackgroundResultSelf-citationPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“Pancreatitis was thoroughly monitored as an adverse event of interest in this study because a possible association between incretin-based therapies and pancreatitis in patients with T2DM has been suggested in published reports [16].”
Background
Research works printed but not linked: 12
- 10.2337/dc12-0413 · DOI · Paper page
- 10.2337/dc08-1035 · DOI · Paper page
- 10.1111/j.1742-1241.2008.01933.x · DOI · Paper page
- 10.1111/j.1463-1326.2011.01463.x · DOI
- 10.1111/j.1532-5415.2009.02484.x · DOI · Paper page
- 10.1111/j.1463-1326.2009.01124.x · DOI · Paper page
- Takeda Pharmaceuticals America, Inc., 2013, Nesina (alogliptin) Tablets. Package Insert
- 10.1111/ijcp.12119 · DOI
- Food and Drug Administration, 2008, Guidance For Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
- 10.1111/dom.12093 · DOI · Paper page
- 10.1007/s00125-011-2447-3 · DOI
- 10.1185/030079905X49662 · DOI
Cited by
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
“hypoglycemia results in higher HbA1c (146,149,150).”
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Mechanisms of diabetes mellitus-induced bone fragility
On behalf of the IOF Bone and Diabetes Working Group, Napoli, N., Chandran, M., Pierroz, D. D., Abrahamsen, B., Schwartz, A. V., & Ferrari, S. L. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.153 · Cited by 1,107
Clinical Use of DPP-4 Inhibitors
Gallwitz, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00389 · Cited by 374
Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001992 · Cited by 143
Metadata
- Authors
- Del Prato, S., Camisasca, R., Wilson, C., & Fleck, P.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-09-25
- Volume
- 16
- Issue
- 12
- Pages
- 1239-1246
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1981478931
- Cited by
- 87
- References
- 5
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Takeda Development Center Americas, Inc (N/A)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.